Breaking News, Collaborations & Alliances

Intravacc Completes Project for Provention Bio’s Vax Candidate

Potentially the first preventive vaccine for coxsackievirus B, a risk factor associated with type 1 diabetes and celiac disease.

By: Contract Pharma

Contract Pharma Staff

Contract development and manufacturing organization (CDMO) Intravacc, said that a candidate polyvalent inactivated coxsackievirus B (CVB) vaccine it developed and manufactured for Provention Bio in less than 36 months, has entered into a first in human Phase I clinical study called PROVENT (PROtocol for coxsackievirus Vaccine in healthy volunteers).   Provention Bio is a clinical stage biopharmaceutical company, that selected Intravacc in 2018 to lead product development and manufacturing of cli...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters